Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) appears to be an independent risk factor for the development of cardiovascular co-morbidities, such as coronary artery disease and heart failure (HF).1 It should be highlighted that patients with both COPD and HF seem to have a significantly increased risk for readmission owing to HF and all-cause mortality.2 Thus, it is of utmost importance to decrease morbidity and mortality in subjects with coexisting COPD and cardiovascular disease.3